Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
B: Arm Label: Bevacizumab + IFN-Alfa-2A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab [Avastin], Drug: Interferon alfa 2a [Roferon] | Arm Label: Placebo + IFN-Alfa-2A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Interferon alfa 2a [Roferon], Drug: Placebo | Intervention Type: DRUG; Name: Bevacizumab [Avastin]; Assigned to Arm(s): Bevacizumab + IFN-Alfa-2A | Intervention Type: DRUG; Name: Interferon alfa 2a [Roferon]; Assigned to Arm(s): Bevacizumab + IFN-Alfa-2A, Placebo + IFN-Alfa-2A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + IFN-Alfa-2A
C: Arm Label: Arm S: Nivolumab + Sunitinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Sunitinib | Arm Label: Arm P: Nivolumab + Pazopanib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Pazopanib | Arm Label: Arm I-1: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I-3: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm IN-3: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab, Arm P: Nivolumab + Pazopanib, Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Pazopanib; Assigned to Arm(s): Arm P: Nivolumab + Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab
D: Arm Label: ccRCC molecular subgroup 1: 1A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 1: 1B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 4: 4A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 4: 4B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 2: 2C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Arm Label: ccRCC molecular subgroup 2: 2B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1A, ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4A, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C

Answer: A